

Amit V Khera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/734678/publications.pdf>

Version: 2024-02-01

119
papers

20,342
citations

32410

55
h-index

21843

118
g-index

139
all docs

139
docs citations

139
times ranked

28188
citing authors

#	ARTICLE	IF	CITATIONS
1	Rare coding variants in 35 genes associate with circulating lipid levelsâ€”A multi-ancestry analysis of 170,000 exomes. <i>American Journal of Human Genetics</i> , 2022, 109, 81-96.	2.6	24
2	Response by Patel and Khera to Letter Regarding Article, â€œQuantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals: Results From the UK Biobank Prospective Cohort Studyâ€• <i>Circulation</i> , 2022, 145, e147-e148.	1.6	0
3	<i>CYP2C19</i> Genotyping in Anticoagulated Patients After Percutaneous Coronary Intervention: Should It Be Routine?. <i>Circulation</i> , 2022, 145, 721-723.	1.6	1
4	A single-cell atlas of human and mouse white adipose tissue. <i>Nature</i> , 2022, 603, 926-933.	13.7	277
5	Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease. <i>JAMA Network Open</i> , 2022, 5, e223849.	2.8	136
6	Association of the Interaction Between Familial Hypercholesterolemia Variants and Adherence to a Healthy Lifestyle With Risk of Coronary Artery Disease. <i>JAMA Network Open</i> , 2022, 5, e222687.	2.8	17
7	Analyzing human knockouts to validate GPR151 as a therapeutic target for reduction of body mass index. <i>PLoS Genetics</i> , 2022, 18, e1010093.	1.5	1
8	Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores. <i>Nature Genetics</i> , 2022, 54, 450-458.	9.4	109
9	Association of Pathogenic DNA Variants Predisposing to Cardiomyopathy With Cardiovascular Disease Outcomes and All-Cause Mortality. <i>JAMA Cardiology</i> , 2022, 7, 723.	3.0	15
10	Rare and Common Genetic Variation Underlying the Risk of Hypertrophic Cardiomyopathy in a National Biobank. <i>JAMA Cardiology</i> , 2022, 7, 715.	3.0	22
11	Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults. <i>Journal of the American Heart Association</i> , 2022, 11, e025192.	1.6	7
12	The potential of polygenic scores to improve cost and efficiency of clinical trials. <i>Nature Communications</i> , 2022, 13, .	5.8	19
13	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> , 2022, 54, 761-771.	9.4	68
14	Association of Genome-Wide Polygenic Risk Score for Body Mass Index With Cardiometabolic Health From Childhood Through Midlife. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, .	1.6	4
15	Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots. <i>Nature Communications</i> , 2022, 13, .	5.8	43
16	Polygenic Score Assessed in Young Adulthood and Onset of Subclinical Atherosclerosis and Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2022, 80, 280-282.	1.2	10
17	Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 465-474.	1.1	104
18	Transethnic Transferability of a Genome-Wide Polygenic Score for Coronary Artery Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003092.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. <i>Gastroenterology</i> , 2021, 160, 1620-1633.e13.	0.6	68
20	Performance of Atrial Fibrillation Risk Prediction Models in Over 4 Million Individuals. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e008997.	2.1	30
21	Genetic Predictor to Identify Individuals With High Lipoprotein(a) Concentrations. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003182.	1.6	10
22	Predicting Risk of Hypertension Among Childhood Cancer Survivors. <i>JACC: CardioOncology</i> , 2021, 3, 85-87.	1.7	1
23	Improving reporting standards for polygenic scores in risk prediction studies. <i>Nature</i> , 2021, 591, 211-219.	13.7	265
24	Concordance of a High Polygenic Score Among Relatives. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003262.	1.6	16
25	Randomized prospective evaluation of genome sequencing versus standard-of-care as a first molecular diagnostic test. <i>Genetics in Medicine</i> , 2021, 23, 1689-1696.	1.1	17
26	Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals. <i>Circulation</i> , 2021, 144, 410-422.	1.6	72
27	B-PO02-164 GENOME-WIDE POLYGENIC RISK SCORE PREDICTS SUDDEN ARRHYTHMIC DEATH IN PATIENTS WITH CORONARY ARTERY DISEASE. <i>Heart Rhythm</i> , 2021, 18, S164-S165.	0.3	0
28	Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies. <i>European Heart Journal</i> , 2021, 42, 3388-3403.	1.0	114
29	Perspectives on Identifying and Treating Familial Hypercholesterolemia in Childhood. <i>Clinical Chemistry</i> , 2021, 67, 1312-1317.	1.5	1
30	Rare, Damaging DNA Variants in <i>CORIN</i> and Risk of Coronary Artery Disease: Insights From Functional Genomics and Large-Scale Sequencing Analyses. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003399.	1.6	10
31	Design and user experience testing of a polygenic score report: a qualitative study of prospective users. <i>BMC Medical Genomics</i> , 2021, 14, 238.	0.7	29
32	Abdominal subcutaneous adipose tissue negatively associates with subclinical coronary artery disease in men with psoriasis. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100231.	1.3	0
33	Selection of 51 predictors from 13,782 candidate multimodal features using machine learning improves coronary artery disease prediction. <i>Patterns</i> , 2021, 2, 100364.	3.1	18
34	Polygenic basis and biomedical consequences of telomere length variation. <i>Nature Genetics</i> , 2021, 53, 1425-1433.	9.4	145
35	Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. <i>Cell Reports Medicine</i> , 2021, 2, 100437.	3.3	56
36	Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases. <i>Nature Metabolism</i> , 2021, 3, 1476-1483.	5.1	43

#	ARTICLE	IF	CITATIONS
37	The power of genetic diversity in genome-wide association studies of lipids. <i>Nature</i> , 2021, 600, 675-679.	13.7	353
38	Machine learning enables new insights into genetic contributions to liver fat accumulation. <i>Cell Genomics</i> , 2021, 1, 100066.	3.0	34
39	Monogenic and Polygenic Contributions to Atrial Fibrillation Risk. <i>Circulation Research</i> , 2020, 126, 200-209.	2.0	79
40	Physiology as a Lingua Franca for Clinical Machine Learning. <i>Patterns</i> , 2020, 1, 100017.	3.1	9
41	Validation of a Genome-Wide Polygenic Score for Coronary Artery Disease in South Asians. <i>Journal of the American College of Cardiology</i> , 2020, 76, 703-714.	1.2	76
42	Heterozygous ABCG5 Gene Deficiency and Risk of Coronary Artery Disease. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, 417-423.	1.6	45
43	Genome-Wide Polygenic Score, Clinical Risk Factors, and Long-Term Trajectories of Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2738-2746.	1.1	71
44	Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. <i>Nature Communications</i> , 2020, 11, 3635.	5.8	277
45	Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. <i>Nature Communications</i> , 2020, 11, 2254.	5.8	140
46	Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2769-2780.	1.2	88
47	What Is Familial Hypercholesterolemia, and Why Does It Matter?. <i>Circulation</i> , 2020, 141, 1760-1763.	1.6	34
48	Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History. <i>JAMA Network Open</i> , 2020, 3, e203959.	2.8	75
49	A structural variation reference for medical and population genetics. <i>Nature</i> , 2020, 581, 444-451.	13.7	614
50	Titin Truncating Variants in Adults Without Known Congestive Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1239-1241.	1.2	22
51	Race, socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a national biobank. <i>International Journal for Equity in Health</i> , 2020, 19, 114.	1.5	101
52	Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002767.	1.6	9
53	A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. <i>PLoS Genetics</i> , 2020, 16, e1008629.	1.5	101
54	Rare Genetic Variants Associated With Sudden Cardiac Death in Adults. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2623-2634.	1.2	27

#	ARTICLE	IF	CITATIONS
55	Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI. <i>Stroke</i> , 2019, 50, 3004-3012.	1.0	31
56	Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction. <i>Circulation</i> , 2019, 139, 1593-1602.	1.6	213
57	Rare Protein-Truncating Variants in <i>APOB</i> , Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002376.	1.6	57
58	RARE PROTEIN-TRUNCATING VARIANTS IN APOB ASSOCIATE WITH LOWER LOW-DENSITY LIPOPROTEIN CHOLESTEROL, LOWER TRIGLYCERIDES, AND REDUCED RISK OF CORONARY HEART DISEASE. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1716.	1.2	1
59	Genetic Association of Finger Photoplethysmography-Derived Arterial Stiffness Index With Blood Pressure and Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1253-1261.	1.1	35
60	Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. <i>Cell</i> , 2019, 177, 587-596.e9.	13.5	516
61	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 140, e596-e646.	1.6	1,789
62	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1376-1414.	1.2	820
63	Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia. <i>New England Journal of Medicine</i> , 2019, 381, 2582-2584.	13.9	21
64	Low coverage whole genome sequencing enables accurate assessment of common variants and calculation of genome-wide polygenic scores. <i>Genome Medicine</i> , 2019, 11, 74.	3.6	70
65	DNA Sequence Variation in <i>ACVR1C</i> Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, 226-234.	0.3	31
66	Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. <i>Nature Communications</i> , 2018, 9, 1613.	5.8	78
67	Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling. <i>Circulation</i> , 2018, 137, 222-232.	1.6	87
68	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. <i>Nature Genetics</i> , 2018, 50, 1514-1523.	9.4	497
69	Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. <i>Nature Genetics</i> , 2018, 50, 1219-1224.	9.4	2,111
70	Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. <i>Nature Communications</i> , 2018, 9, 3391.	5.8	140
71	Genetic inactivation of <i>ANGPTL4</i> improves glucose homeostasis and is associated with reduced risk of diabetes. <i>Nature Communications</i> , 2018, 9, 2252.	5.8	99
72	Genetics of coronary artery disease: discovery, biology and clinical translation. <i>Nature Reviews Genetics</i> , 2017, 18, 331-344.	7.7	448

#	ARTICLE	IF	CITATIONS
73	Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 937.	3.8	148
74	Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 626.	3.8	313
75	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. <i>Diabetes</i> , 2017, 66, 2310-2315.	0.3	20
76	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. <i>Circulation Research</i> , 2017, 121, 81-88.	2.0	68
77	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. <i>Circulation</i> , 2017, 135, 2494-2504.	1.6	180
78	Genetic Predisposition to Abdominal Obesity and Cardiometabolic Risk—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2334.	3.8	4
79	ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2054-2063.	1.2	348
80	Is Coronary Atherosclerosis One Disease or Many?. <i>Circulation</i> , 2017, 135, 1005-1007.	1.6	36
81	Genetic Risk, Lifestyle, and Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1192-1195.	13.9	17
82	Demystifying HDL Cholesterol—A “Human Knockout” to the Rescue?. <i>Clinical Chemistry</i> , 2017, 63, 33-36.	1.5	5
83	Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort. <i>American Journal of Cardiology</i> , 2017, 119, 881-885.	0.7	29
84	Exome-wide association study of plasma lipids in >300,000 individuals. <i>Nature Genetics</i> , 2017, 49, 1758-1766.	9.4	470
85	Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. <i>Nature Genetics</i> , 2017, 49, 1392-1397.	9.4	190
86	A Genetic Variant Associated with Five Vascular Diseases Is a Distal Regulator of Endothelin-1 Gene Expression. <i>Cell</i> , 2017, 170, 522-533.e15.	13.5	356
87	Mendelian Randomization. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1925.	3.8	1,253
88	Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2761-2772.	1.2	186
89	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2578-2589.	1.2	723
90	Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. <i>New England Journal of Medicine</i> , 2016, 375, 2349-2358.	13.9	979

#	ARTICLE	IF	CITATIONS
91	The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1062-1064.	0.8	5
92	Body Fat Distribution and Incident Cardiovascular Disease in Obese Adults. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2150-2151.	1.2	113
93	Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 Diabetics. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1880-1888.	1.1	60
94	Potent peroxisome proliferator-activated receptor- α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. <i>European Heart Journal</i> , 2015, 36, 3020-3022.	1.0	29
95	On-Statins, Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection) Trial. <i>Journal of the American College of Cardiology</i> , 2014, 64, 694-698.	0.7	14
96	Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia. <i>American Journal of Cardiology</i> , 2015, 115, 178-182.	0.7	51
97	Response to Letter Regarding Article, "Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in) Patients With Dyslipidemia." <i>Circulation</i> , 2014, 129, 635-642.	1.6	338
98	Single-cell transcriptomics: an emerging tool in the study of cardiometabolic disease. <i>Journal of Translational Medicine</i> , 2014, 12, 312.	1.8	4
99	Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk. <i>Circulation</i> , 2014, 129, 635-642.	1.6	338
100	Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2013, 15, 1215-1219.	2.9	49
101	The Addition of Niacin to Statin Therapy Improves High-Density Lipoprotein Cholesterol Levels But Not Metrics of Functionality. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1909-1910.	1.2	71
102	Cholesterol Efflux Capacity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1449-1451.	1.1	30
103	Management of Low Levels of High-Density Lipoprotein-Cholesterol. <i>Circulation</i> , 2013, 128, 72-78.	1.6	15
104	Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. <i>Obesity</i> , 2013, 21, E439-47.	1.5	355
105	Fasting for lipid testing: Is it worth the trouble?. <i>Archives of Internal Medicine</i> , 2012, 172, 1710-2.	4.3	5
106	The Anti-Oxidative Capacity of High-Density Lipoprotein Is Reduced in Acute Coronary Syndrome But Not in Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2068-2075.	1.2	105
107	Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis. <i>New England Journal of Medicine</i> , 2011, 364, 127-135.	13.9	1,686
108	Dense Genotyping of Candidate Gene Loci Identifies Variants Associated With High-Density Lipoprotein Cholesterol. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 145-155.	5.1	71

#	ARTICLE	IF	CITATIONS
109	The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels. <i>European Heart Journal</i> , 2011, 32, 963-971.	1.0	67
110	Future Therapeutic Directions in Reverse Cholesterol Transport. <i>Current Atherosclerosis Reports</i> , 2010, 12, 73-81.	2.0	93
111	Effect of Right Ventricular Function and Venous Congestion on Cardiorenal Interactions During the Treatment of Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2010, 105, 511-516.	0.7	120
112	Accuracy of Noninvasively Determined Pulmonary Artery Systolic Pressure. <i>American Journal of Cardiology</i> , 2010, 105, 1192-1197.	0.7	60
113	On-Statin Cholesteryl Ester Transfer Protein Mass and Risk of Recurrent Coronary Events (from the) Tj ETQq1 1 0.784314 rgBT /Overl	0.7	37
114	Polyphenols and Cholesterol Efflux. <i>Circulation Research</i> , 2010, 106, 627-629.	2.0	18
115	Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. <i>Circulation</i> , 2009, 119, 1711-1719.	1.6	117
116	Discovery and Validation of New Molecular Targets in Treating Dyslipidemia: The Role of Human Genetics. <i>Trends in Cardiovascular Medicine</i> , 2009, 19, 195-201.	2.3	19
117	My Most Famous Patient. <i>Academic Medicine</i> , 2008, 83, 1170-1171.	0.8	0
118	Monkeys Pay Per View: Adaptive Valuation of Social Images by Rhesus Macaques. <i>Current Biology</i> , 2005, 15, 543-548.	1.8	361
119	Electronic Health Record-Based Genome-Wide Meta-Analysis Provides New Insights on the Genetic Architecture of Non-Alcoholic Fatty Liver Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2